Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads in formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing heart attack or stroke. Two forms of the condition exist heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obese, family history, high blood pressure, smoking and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives and cholesterol absorption inhibitors.
Report Highlights Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 1, 9, 13, 4, 1, 17, 5 and 3 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 6 molecules, respectively.
Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)
Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
Renal Diseases Drug Development Pipeline Review, 2018 Summary Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The...
Gastrointestinal Diseases Drug Development Pipeline Review, 2018 Summary Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment...
Cardiomyopathy Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Cardiomyopathy Global Clinical Trials Review, H2, 2018" provides an overview of Cardiomyopathy clinical trials scenario.This report provides top line data relating to the clinical trials on Cardiomyopathy. Report...
NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1 or SIRT1 or EC 3.5.1.) - Pipeline Review, H2 2018 Summary NAD Dependent Protein Deacetylase Sirtuin 1 (SIR2 Like Protein 1 or Sirtuin Type 1 or Regulatory Protein SIR2 Homolog 1...
Colitis - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape. Colitis is swelling (inflammation) of the large intestine...
Bone Disorders Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Bone Disorders Global Clinical Trials Review, H2, 2018" provides an overview of Bone Disorders clinical trials scenario.This report provides top line data relating to the clinical trials on Bone Disorders. Report...
House Dust Mite Allergy - Pipeline Review, H1 2019 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide House Dust Mite Allergy - Pipeline Review, H1 2019, provides an overview of the House Dust Mite Allergy (Immunology) pipeline landscape. House dust...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.